Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Published:2014-01 Issue:9911 Volume:383 Page:31-39
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Fuchs Charles S,Tomasek Jiri,Yong Cho Jae,Dumitru Filip,Passalacqua Rodolfo,Goswami Chanchal,Safran Howard,dos Santos Lucas Vieira,Aprile Giuseppe,Ferry David R,Melichar Bohuslav,Tehfe Mustapha,Topuzov Eldar,Zalcberg John Raymond,Chau Ian,Campbell William,Sivanandan Choondal,Pikiel Joanna,Koshiji Minori,Hsu Yanzhi,Liepa Astra M,Gao Ling,Schwartz Jonathan D,Tabernero Josep

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. Chemotherapy for advanced gastric cancer;Wagner;Cochrane Database Syst Rev,2010

3. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model;Jung;Eur J Cancer,2002

4. The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer;Kim;Gut Liver,2009

5. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients;Lieto;Ann Surg Oncol,2008

Cited by 1818 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of angiogenesis-related subtypes and risk models for predicting the prognosis of gastric cancer patients;Computational Biology and Chemistry;2024-10

2. A narrative review on advances in neoadjuvant immunotherapy for esophageal cancer: Molecular biomarkers and future directions;International Journal of Cancer;2024-09-14

3. Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics;Targeted Oncology;2024-09-13

4. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer;Cancer Immunology, Immunotherapy;2024-09-05

5. Hyaluronidase improves the efficacy of nab-paclitaxel after prolonged angiogenesis inhibition in preclinical models for esophagogastric cancer;Biomedicine & Pharmacotherapy;2024-09